CN115778939B - Dt-10在制备抗真菌药物和日用品中的应用 - Google Patents
Dt-10在制备抗真菌药物和日用品中的应用 Download PDFInfo
- Publication number
- CN115778939B CN115778939B CN202210730793.7A CN202210730793A CN115778939B CN 115778939 B CN115778939 B CN 115778939B CN 202210730793 A CN202210730793 A CN 202210730793A CN 115778939 B CN115778939 B CN 115778939B
- Authority
- CN
- China
- Prior art keywords
- cell membrane
- antifungal
- candida albicans
- daily necessities
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 230000000843 anti-fungal effect Effects 0.000 title claims abstract description 16
- 229940121375 antifungal agent Drugs 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims abstract description 13
- 241000222122 Candida albicans Species 0.000 claims abstract description 16
- 229940095731 candida albicans Drugs 0.000 claims abstract description 16
- 201000007336 Cryptococcosis Diseases 0.000 claims abstract description 11
- 241000221204 Cryptococcus neoformans Species 0.000 claims abstract description 11
- 241001225321 Aspergillus fumigatus Species 0.000 claims abstract description 9
- 229940091771 aspergillus fumigatus Drugs 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 6
- 241000233866 Fungi Species 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 abstract description 21
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 abstract description 16
- 229960004884 fluconazole Drugs 0.000 abstract description 16
- 230000001580 bacterial effect Effects 0.000 abstract description 10
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 9
- 230000035699 permeability Effects 0.000 abstract description 7
- 150000003904 phospholipids Chemical class 0.000 abstract description 7
- 241000675278 Candida albicans SC5314 Species 0.000 abstract description 6
- 206010017533 Fungal infection Diseases 0.000 abstract description 6
- 208000031888 Mycoses Diseases 0.000 abstract description 6
- 230000009471 action Effects 0.000 abstract description 5
- 238000001514 detection method Methods 0.000 abstract description 3
- 230000007246 mechanism Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 230000003013 cytotoxicity Effects 0.000 abstract description 2
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 25
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 12
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 12
- 229960003942 amphotericin b Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000002538 fungal effect Effects 0.000 description 8
- 229960000988 nystatin Drugs 0.000 description 7
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 5
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 5
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 5
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 5
- 229930014626 natural product Natural products 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- SFAYBQDGCKZKMH-UHFFFAOYSA-N BNCC Chemical compound BNCC SFAYBQDGCKZKMH-UHFFFAOYSA-N 0.000 description 4
- ALFNTRJPGFNJQV-UHFFFAOYSA-N Cajanin Chemical compound C=1C(OC)=CC(O)=C(C2=O)C=1OC=C2C1=CC=C(O)C=C1O ALFNTRJPGFNJQV-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 210000003850 cellular structure Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 3
- 229960004413 flucytosine Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 208000036641 Aspergillus infections Diseases 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000008686 ergosterol biosynthesis Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 150000004291 polyenes Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 244000105627 Cajanus indicus Species 0.000 description 1
- 235000010773 Cajanus indicus Nutrition 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010049047 Echinocandins Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000037026 Invasive Fungal Infections Diseases 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- -1 isopentenyl Chemical group 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了DT‑10在制备抗真菌药物和日用品中的应用。DT‑10对氟康唑耐药和敏感白色念珠菌都具有抑制活性，最小抑菌浓度(MIC)为3.125‑12.5μg/mL。作用机理研究表明，DT‑10能够结合细胞膜磷脂，进而增强白色念珠菌SC5314细胞膜渗透性，同时降低细胞膜流动性。该作用机制使DT‑10能够迅速杀菌，在16×MIC浓度下，处理20min时能够将活性菌量控制在检测线以下，故不易产生耐药性。另外，DT‑10对新生隐球菌和烟曲霉也具有较强抑制活性。鉴于DT‑10低细胞毒性和强抗真菌活性，可用于制备预防或治疗真菌感染的药物，也可用于制备抗真菌日用品。
Description
技术领域：
本发明属于天然产物结构优化物领域，具体涉及天然产物木豆素C结构优化物DT-10在制备抗真菌药物或抗真菌日用品中的应用。
背景技术：
近年来，免疫力低下人群数量不断增加，这也导致侵袭性真菌感染越发严重。真菌感染行动基金组织(GAFFI)统计数据显示，每年有超过3亿人患上严重的真菌感染疾病，其中大约有200万人会因为真菌感染而死亡。其中，念珠菌属、隐球菌属和曲霉属是三大主要致病菌属，它们能够侵袭免疫力低下人群，例如器官移植、肿瘤化疗、人类免疫缺陷病毒(HIV)感染患者，成为导致患者死亡的真正原因。
目前，临床上用于治疗真菌感染的药物种类较少，主要有三大类，包括唑类、多烯类和棘白菌素类。这三大类抗真菌药物不仅抗菌谱窄，而且副作用强，很难满足临床真菌治疗需求。更糟糕的是，在本就缺乏抗真菌药物的情况下，真菌耐药问题日益突出，给真菌治疗带来难度。因此，抗真菌药物的研发迫在眉睫。
天然产物是新药开发的重要来源。DT-10是天然产物木豆素C(Longistylin C，LGC)异戊烯基环化产物，其结构优化物DT-10的结构式如下所示：
公开于专利CN102276433A中。但是本专利之前未发现任何与DT-10抗真菌的研究报道。
发明内容：
本发明的目的是提供化合物DT-10在制备抗真菌药物或抗真菌日用品中的应用。
本发明通过实验表明，DT-10不仅能够抑制氟康唑敏感白色念珠菌SC5314和临床分离菌株11D、11E以及11F，而且对氟康唑耐药白色念珠菌ATCC10231、CMCC(F)98001、BNCC186382、BNCC337321和临床分离菌株CA632、CWQ1、CWQ2也具有较强的抑制活性，其最小抑菌浓度MIC为3.125-12.5μg/mL。作用机理研究表明，DT-10通过结合细胞膜磷脂，增加膜渗透性，降低膜流动性。同时，在16×MIC浓度下，DT-10在20min内能够将活性菌量降低至检测线以下，故不易产生耐药性。另外，DT-10对氟康唑耐药新生隐球菌BNCC339771的MIC＝3.125μg/mL，对烟曲霉BNCC 340016的MIC＝12.5μg/mL。
因此，本发明的第一个目的是提供化合物DT-10在制备抗真菌药物中的应用；
所述的化合物DT-10的结构式如下所示：
本发明的第二个目的是提供一种抗真菌感染的药物，其含有化合物DT-10作为活性成分。
优选，所述的药物以化合物DT-10为活性成分和其他药物赋形剂或载体制成。
优选，所述的真菌包括但不限于白色念珠菌、新生隐球菌和烟曲霉感染。
优选，所述的药物可以是颗粒剂、胶囊剂、片剂、散剂、滴丸剂、缓释剂或注射剂中的任意一种或多种。
本发明第三个目的是提供一种防止真菌感染或污染的日用品，其含有化合物DT-10作为活性成分。
优选，所述的真菌包括但不限于白色念珠菌、新生隐球菌和烟曲霉感染。
优选，所述的日用品包括但不限于包括但不限于衣物消毒液、洗手消毒液、化妆品、洗发水、阴道洗液或漱口水。
化合物DT-10是天然产物木豆素C结构优化物，具有比LGC更低的细胞毒性(ShanYan，et al.Chinese Journal of Natural Medicines.2015)。进一步研究发现，DT-10对白色念珠菌、新生隐球菌和烟曲霉具有较强抑制活性，可用于制备抗真菌的药物或抗真菌日用品。
附图说明：
图1是DT-10结合细胞膜磷脂活性图，注：PG，phosphatidylglycerol，磷脂酰甘油；PE，phosphatidylethanolamine，磷脂酰乙醇胺；CL，cardiolipin，心磷脂。
图2是DT-10增大细胞膜渗透性图。
图3是DT-10降低细胞膜流动性图。
图4是DT-10和LGC溶血活性测定图，注：T，代表Triton-X-100。
图5是DT-10杀菌时间图。
具体实施方式：
下面通过实施例进一步描述本发明，但本发明并不局限于这些实施方式，任何在本实施例基本精神层面的改进或代替，仍属于本发明权利要求所保护的范围。
实施例1：DT-10抑菌活性测定
1、仪器和设备
96孔细胞培养板(康宁)、生物安全柜、恒温振荡器、恒温培养箱、万分之一天平。
2、菌株
白色念珠菌(Candida albicans)标准菌株SC5314由安徽中医药大学邵菁教授惠赠，BNCC菌株购买于北纳生物-河南省工业微生物菌种工程技术研究中心，白色念珠菌临床分离菌株CA632、CWQ1、CWQ2、11D、11E、11F由山东大学常文强副教授惠赠，其他菌种为实验室保存菌株。
3、试剂配制
(1)DT-10母液和工作液配制：称取化合物DT-10粉末10mg，溶解于1mL DMSO(麦克林公司)，即得到10mg/mL DMSO母液，-20℃保存。取母液40μL，加入80μL DMSO，即得到4mg/mL工作液。
(2)抗生素母液配制：氟康唑(Fluconazole)、两性霉素B(Amphotericin B)和制霉菌素(Nystatin)母液和工作液配制方法同DT-10。
(3)RPMI-1640培养基：称取RPMI-1640粉末10.4g和MOPS粉末34.53g，加入1L灭菌去离子水，完全溶解后用NaOH调节pH至7.0。用0.22μm的无菌滤膜过滤除菌，4℃保存。
(4)YPD固体培养基：称取蛋白胨20g、葡萄糖20g、酵母提取物10g、琼脂粉20g，加入1L去离子水，高温高压灭菌。
(5)YPD液体培养基：称取蛋白胨20g、葡萄糖20g、酵母提取物10g，加入1L去离子水，高温高压灭菌。
(6)PDA固体培养基：马铃薯200g切成小块，加入800mL去离子水煮沸20min，纱布过滤，称取葡萄糖20g和琼脂15～20g，加入到滤液中，去离子水定容至1L，高温高压灭菌。
4、实验方法
(1)白色念珠菌和新生隐球菌测试方法：
将白色念珠菌和新生隐球菌接种于YPD固体培养基，30℃，培养2d。挑取菌落于YPD液体培养基，30℃，200rpm，培养至指数生长后期。取该菌液10μL再次接种于1mL YPD液体培养基，30℃，200rpm，培养至指数生长期。血细胞计数板计数，用RPMI-1640培养基调整菌液浓度为1×104CFU/mL。96孔细胞培养板第一行加入195μL菌液和5μL待测化合物工作液，其余孔各加入100μL菌液，取第一行孔中的液体100μL于第二行孔中，依次二倍梯度稀释。将96孔细胞培养板置于37℃恒温培养箱中，白色念珠菌24h后观察最小抑菌浓度MIC值，新生隐球菌48h后观察MIC值。肉眼观察每孔菌生长情况，以不生长菌落孔对应的浓度为最小抑菌浓度。
(2)烟曲霉测试方法：
将烟曲霉接种到PDA培养基，置于30℃培养5d，用PRMI-1640培养基冲洗平板，获得孢子悬浮液，血细胞计数板计数，将孢子悬浮液浓度调整为1×105CFU/mL。化合物对烟曲霉的抑制活性测定方法同白色念珠菌。
5、实验结果
表1
如表1所示，DT-10对新生隐球菌、烟曲霉和白色念珠菌都具有较强的杀菌活性，其MIC值为3.125-12.5μg/mL。其中，新生隐球菌BNCC 339771、烟曲霉BNCC 340016、白色念珠菌(ATCC10231、CMCC(F)98001、BNCC 186382和BNCC 337321)以及白色念珠菌临床分离菌株(CA632、CWQ1和CWQ2)皆为氟康唑(FCZ)耐药菌株，DT-10对这些菌株都有抑制活性。
实施例2：DT-10结合细胞膜磷脂
1、试剂
细胞膜磷脂成分磷脂酰甘油(Sigma-Aldrich,841188P)和磷脂酰乙醇胺(Sigma-Aldrich,840027P)溶解于甲醇，心磷脂(Sigma-Aldrich，C1649)为5mg/mL乙醇溶液，麦角甾醇(ALFA，AB0565)溶解于乙醇。
2、实验方法
使用棋盘肉汤稀释法探究不同细胞膜成分对DT-10和两性霉素B抗菌活性的影响。在96孔板中加入50μL RPMI-1640培养基，第一行前10个孔中加入相应浓度的DT-10或两性霉素B，第一行后两个孔中加入待研究细胞成分，依次向下倍比稀释至第八行。在第一列各孔中加入对应浓度待研究细胞成分，依次从左到右倍比稀释至第8列，室温孵育3h。随后，第10和12列加入50μL RPMI-1640培养基，其他列全部加入50μL稀释好的白色念珠菌SC5314菌液。96孔板置于37℃培养18h后测定OD600吸光度。
3、实验结果
两性霉素B为多烯类抗真菌药物，它能够结合真菌细胞膜上的麦角甾醇，进而改变真菌细胞膜的通透性。如图1所示，体系中加入麦角甾醇能够明显降低两性霉素B抑菌活性，而细胞膜磷脂(心磷脂、磷脂酰乙醇胺和磷脂酰甘油)对其活性没有显著影响。与两性霉素B相反，细胞膜磷脂能够明显降低DT-10抑菌活性，而麦角甾醇对其影响不明显。
实施例3：DT-10增大细胞膜渗透性
1、实验方法
稀释好的白色念珠菌SC5314菌液分别加入终浓度1/2×MIC的DT-10或氟康唑，阴性对照加入等体积DMSO。同时加入终浓度为80μg/mL的DAPI和10μM的SYTOX-Green，37℃摇菌5、15、30、60min取样，PBS缓冲液清洗后分别测定激发波长364nm/发射波长454nm和激发波长488nm/发射波长538nm处的荧光强度。
2、实验结果
氟康唑(FCZ)能够特异性干扰真菌细胞色素P450，进而抑制细胞膜上麦角固醇的合成并杀死真菌细胞。如图2所示，与阴性对照DMSO组相比，随着氟康唑处理时间延长，细胞中荧光强度增加不明显，而DT-10处理5min便可导致荧光强度显著增加，说明DT-10能够破坏细胞膜，增加膜渗透性。
实施例4：DT-10降低细胞膜流动性
1、实验方法
稀释好的白色念珠菌SC5314菌液加入终浓度2μmol/L的Laurdan染液(DMSO溶解)，37℃摇菌10min后菌液加入终浓度1/2×、1×、2×MIC的DT-10，加入终浓度50mM的苯甲醇(Benzyl alcohol)为阳性对照，加入等体积DMSO为阴性对照。处理40min后PBS缓冲液清洗，酶标仪分别测定激发波长350nm/发射波长435nm和激发波长350nm/发射波长500nm处的荧光强度，计算广义偏振度GP值，GP＝(435nm荧光强度-500nm荧光强度)/(435nm荧光强度+500nm荧光强度)。GP值为-1和+1分别代表最高和最低膜流动性。
2、实验结果
如图3所示，DT-10能够明显降低细胞膜流动性，而且随着DT-10浓度增加，流动性降低越明显。
实施例5：DT-10和LGC溶血活性测定
1、实验方法
无菌脱纤维羊血PBS清洗三次后加入二倍梯度稀释的DT-10或LGC，37℃孵育1h，2500rpm离心，吸取上清测定543nm吸光度。等体积DMSO为阴性对照，0.2％Triton-X-100为阳性对照。每个样品3个技术重复，实验进行3次生物学重复。
2、实验结果：
如图4所示，在浓度为256μg/mL(白色念珠菌MIC值的40倍)时，DT-10溶血活性可忽略，而LGC却表现出明显增高的溶血活性。
实施例6：杀菌时间测定
1、实验方法
调整好的白色念珠菌SC5314菌液分别加入终浓度为8×和16×MIC的DT-10、制霉菌素(NST)、两性霉素B(AMP)、氟康唑(FCZ)和5-氟胞嘧啶(5-F)，加入等体积的DMSO为阴性对照。37℃摇菌处理20min后分别10倍梯度稀释进行菌落平板计数。
2、实验结果
两性霉素B和制霉菌素能够结合细胞膜上的麦角甾醇，增强细胞膜渗透性，进而将细胞杀死；氟康唑通过干扰真菌细胞色素P450抑制麦角甾醇的合成,从而起到灭杀真菌细胞的作用；5-氟胞嘧啶通过干扰DNA和蛋白质合成来发挥抗真菌作用。通过作用方式可知，两性霉素B和制霉菌素能够直接杀菌，因此在该两种药物处理下细胞快速死亡。而氟康唑和5-氟胞嘧啶通过抑制细胞成分合成方式导致细胞死亡，因此在这两种药物处理下细胞死亡速度相对较慢。如图5所示，DT-10表现出比制霉菌素和两性霉素B更快的杀菌速度，在16×MIC处理浓度下，20min内DT-10能够将活性菌量降低至检测线以下。
Claims (3)
1.化合物DT-10在制备抗真菌药物中的应用，所述的真菌为白色念珠菌、新生隐球菌或烟曲霉；
所述的化合物DT-10的结构式如下所示：
。
2.根据权利要求1所述的应用，其特征在于，所述的药物以化合物DT-10为活性成分和其他药物赋形剂或载体制成。
3.根据权利要求1所述的应用，其特征在于，所述的药物是颗粒剂、胶囊剂、片剂、散剂、滴丸剂、缓释剂或注射剂中的任意一种。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210730793.7A CN115778939B (zh) | 2022-06-24 | 2022-06-24 | Dt-10在制备抗真菌药物和日用品中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210730793.7A CN115778939B (zh) | 2022-06-24 | 2022-06-24 | Dt-10在制备抗真菌药物和日用品中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115778939A CN115778939A (zh) | 2023-03-14 |
| CN115778939B true CN115778939B (zh) | 2024-03-29 |
Family
ID=85431209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210730793.7A Active CN115778939B (zh) | 2022-06-24 | 2022-06-24 | Dt-10在制备抗真菌药物和日用品中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115778939B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102276433A (zh) * | 2011-06-30 | 2011-12-14 | 南昌大学 | 木豆素c及其衍生物及其在制备抗癌药物中的应用 |
| CN103172512A (zh) * | 2011-12-23 | 2013-06-26 | 中国医学科学院医药生物技术研究所 | 一组木豆素结构类似化合物、制备方法和应用 |
-
2022
- 2022-06-24 CN CN202210730793.7A patent/CN115778939B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102276433A (zh) * | 2011-06-30 | 2011-12-14 | 南昌大学 | 木豆素c及其衍生物及其在制备抗癌药物中的应用 |
| CN103172512A (zh) * | 2011-12-23 | 2013-06-26 | 中国医学科学院医药生物技术研究所 | 一组木豆素结构类似化合物、制备方法和应用 |
Non-Patent Citations (1)
| Title |
|---|
| New Monomeric Stilbenoids from Peanut (Arachis hypogaea) Seeds Challenged by an Aspergillus flavus Strain.;Victor S. Sobolev等;J. Agric. Food Chem.;第64卷;第579−584页，特别是摘要，第580页图1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115778939A (zh) | 2023-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ogbolu et al. | In vitro antimicrobial properties of coconut oil on Candida species in Ibadan, Nigeria | |
| Endo et al. | Potent antifungal activity of extracts and pure compound isolated from pomegranate peels and synergism with fluconazole against Candida albicans | |
| Tong et al. | Antimicrobial activities of endophytic fungal isolates from medicinal herb Orthosiphon stamineus Benth | |
| Wu et al. | Synthetic β-sheet forming peptide amphiphiles for treatment of fungal keratitis | |
| Jia et al. | Silver nanoparticles offer a synergistic effect with fluconazole against fluconazole-resistant Candida albicans by abrogating drug efflux pumps and increasing endogenous ROS | |
| Chatterjee et al. | Inhibition of biofilm-and hyphal-development, two virulent features of Candida albicans by secondary metabolites of an endophytic fungus Alternaria tenuissima having broad spectrum antifungal potential | |
| Nenoff et al. | In vitro susceptibility testing of yeasts to nystatin–low minimum inhibitory concentrations suggest no indication of in vitro resistance of Candida albicans, Candida species or non-Candida yeast species to nystatin | |
| Yan et al. | Antifungal activity and inhibitory mechanisms of ferulic acid against the growth of Fusarium graminearum | |
| Blanco et al. | Efficacy of a fixed combination of tetracycline, chloramphenicol, and colistimethate sodium for treatment of Candida albicans keratitis | |
| Latha et al. | Effects of Vernonia cinerea Less methanol extract on growth and morphogenesis of Candida albicans | |
| CN107828665A (zh) | 一种竹叶兰内生真菌的分离纯化方法及其应用 | |
| CN111419841A (zh) | 一种抗白色念珠菌组合药物 | |
| CN110251497A (zh) | 盐酸氯苯胍在制备治疗真菌感染药物中的应用 | |
| CN115778939B (zh) | Dt-10在制备抗真菌药物和日用品中的应用 | |
| Muthamil et al. | Inhibitory effect of Murraya koenigii against Candida albicans virulence and biofilm development | |
| MX2007011885A (es) | Un metodo para prevenir y/o tratar infecciones vaginales y de vulva. | |
| Shi et al. | The effect of anti-amoebic agents and Ce6-PDT on Acanthamoeba castellanii trophozoites and cysts, in vitro | |
| CN114601829B (zh) | 一种n2化合物在制备抗真菌的药物中的应用 | |
| Campos et al. | Antifungal activity of palmatine against strains of Candida spp. resistant to azoles in planktonic cells and biofilm | |
| CN104188962A (zh) | 厚朴酚与唑类药物在制备抗真菌联合用药物中的应用 | |
| CN107261146B (zh) | 一种鱼腥草素钠制备杀灭耐药烟曲霉的组合物及其应用 | |
| Polacheck et al. | The susceptibility of Cryptococcus neoformans to an antimycotic agent (G2) from alfalfa | |
| Hussein et al. | In Vitro Study the Effects of Anti-ungal Agents on the Mycelial Growth of Aspergillus Niger | |
| Daruliza et al. | Anti-Candida activity and brine shrimp toxicity assay of Ganoderma boninense | |
| Homa et al. | In vitro activity of calcium channel blockers in combination with conventional antifungal agents against clinically important filamentous fungi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |